LORAZEPAM Drug Patent Profile
✉ Email this page to a colleague
When do Lorazepam patents expire, and what generic alternatives are available?
Lorazepam is a drug marketed by Amneal Pharms, Chartwell Molecular, Hikma, Lupin Ltd, Pharm Assoc, Bedford, Dava Pharms Inc, Dr Reddys, Epic Pharma Llc, Hospira, Intl Medication Sys, Rising, Watson Labs, Roxane, Am Therap, Anda Repository, Ani Pharms, Aurolife Pharma Llc, Chartwell Rx, Halsey, Leading, Mutual Pharm, Oxford Pharms, Par Pharm, Sandoz, Sun Pharm Inds Ltd, Superpharm, Usl Pharma, Warner Chilcott, and Bedford Labs. and is included in sixty-four NDAs.
The generic ingredient in LORAZEPAM is lorazepam. There are eleven drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the lorazepam profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lorazepam
A generic version of LORAZEPAM was approved as lorazepam by SANDOZ on April 21st, 1987.
Summary for LORAZEPAM
US Patents: | 0 |
Applicants: | 30 |
NDAs: | 64 |
Finished Product Suppliers / Packagers: | 33 |
Raw Ingredient (Bulk) Api Vendors: | 50 |
Clinical Trials: | 195 |
Patent Applications: | 4,382 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for LORAZEPAM |
Drug Sales Revenues: | Drug sales revenues for LORAZEPAM |
What excipients (inactive ingredients) are in LORAZEPAM? | LORAZEPAM excipients list |
DailyMed Link: | LORAZEPAM at DailyMed |
Recent Clinical Trials for LORAZEPAM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Colorado, Denver | Phase 2 |
Children's Hospital Los Angeles | Phase 2 |
University of Calgary | Phase 2 |
Pharmacology for LORAZEPAM
Drug Class | Benzodiazepine |